BridgeBio announced that on August 6, 2024, the compensation committee of BridgeBio’s board of directors approved equity grants to 17 new employees in restricted stock units for an aggregate of 71,859 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on August 16, 2025, with one-twelfth of the remaining shares underlying each such employee’s restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee’s continued employment with the Company or one of its subsidiaries on such vesting dates. All of the above-described awards were made under BridgeBio’s Amended and Restated 2019 Inducement Equity Plan.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- BridgeBio price target lowered to $45 from $46 at Citi
- BridgeBio reports Q2 EPS (39c), consensus ($1.04)
- BridgeBio Pharma Announces Key Executive Leadership Shuffle
- BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer